Physician profile
Jay Mitchell Pribble
NPI 1508097155
$5,141.59
in general payments reported to CMS, 2019-2025
34 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $1,130 · 2023: $1,170 · 2024: $1,362 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $742.29 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $688.50 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $489.82 | 2021-2024 | |
| Glaxosmithkline, LLC. | $449.02 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.94 | 2021-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $296.54 | 2023-2024 | |
| Pfizer INC. | $285.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.84 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $123.99 | 2021-2023 | Belsomra |
| Integra Lifesciences Corporation | $109.48 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Exact Sciences Corporation | $105.58 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $99.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.08 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Eisai INC. | $81.33 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $78.01 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $77.78 | 2025 | Inspire |
| Genzyme Corporation | $75.21 | 2025 | |
| Amgen INC. | $72.92 | 2024-2025 | Otezla, Repatha, Tezspire |
| Abbott Laboratories | $66.81 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $58.31 | 2023-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $54.62 | 2025 | Dupixent |
| Genentech USA, INC. | $44.82 | 2021 | |
| Hikma Pharmaceuticals USA | $35.01 | 2025 | Ryaltris |
| Stryker Corporation | $30.53 | 2025 | Xpress Loprofile |
| Arbor Pharmaceuticals, INC. | $29.09 | 2021 | |
| Boston Scientific Corporation | $27.48 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Optinose US, INC. | $26.31 | 2025 | |
| Alk-Abello, INC | $24.10 | 2025 | Neffy, Odactra, Ragwitek |
| Sumitomo Pharma America, INC. | $23.91 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $19.23 | 2024 | Rexulti |
| Medtronic, INC. | $16.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Pribble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.